Internal Medicine, Hematology & Oncology · Charlottesville, VA
NPI
1093884611
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1240 Lee St
Charlottesville, VA, 22908
Phone (434) 924-9333
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
360 services
Medicare patients, 2024
98
Average age 67
Drug cost, 2024
$1.4M
359 prescriptions
Company payments, 2025
$121
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael G Douvas was code 99232 (hospital e&m - subsequent), 155 times for 35 patients. In total Michael G Douvas billed 360 services in 12 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 155 | 35 | $60.01 | $9,302 |
| 99214 Office E&M - Established | Facility | 139 | 52 | $64.84 | $9,012 |
| 99238 Hospital Discharge Management | Facility | 14 | 13 | $61.74 | $864 |
By year: 2022 $29K for 418 services; 2023 $30K for 422 services; 2024 $25K for 360 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael G Douvas prescribed most often to Medicare patients was Sprycel (Dasatinib), with 27 prescriptions and refills. In total Michael G Douvas wrote 359 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sprycel Dasatinib | 27 | 27 | Under 11 | $259K |
| Imatinib Mesylate Generic | 23 | 23 | Under 11 | $38K |
| Eliquis Apixaban | 15 | 17 | Under 11 | $10K |
| Nivestym Filgrastim-Aafi | 14 | 14 | Under 11 | $17K |
| Ondansetron Hcl Generic | 14 | 14 | Under 11 | $96.04 |
| Acyclovir Generic | 14 | 36 | Under 11 | $348 |
| Valacyclovir Valacyclovir Hcl | 13 | 13 | Under 11 | $737 |
| Sorafenib Sorafenib Tosylate | 13 | 13 | Under 11 | $141K |
| Sunitinib Malate Generic | 13 | 13 | Under 11 | $72K |
| Revlimid Lenalidomide | 12 | 12 | Under 11 | $206K |
| Calquence Acalabrutinib Maleate | 12 | 12 | Under 11 | $162K |
| Amlodipine Besylate Generic | 11 | 31 | Under 11 | $39.25 |
| Furosemide Generic | 11 | 11 | Under 11 | $40.59 |
| Pomalyst Pomalidomide | 11 | 11 | Under 11 | $199K |
Brand drugs: 115 claims; generic drugs: 244 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael G Douvas $121 ($121 in general payments such as food, travel and fees) from 2 companies. The largest payer was Sobi, Inc with $121.
| Company | Payments | Amount |
|---|---|---|
| Sobi, Inc SOBI.ST | 1 | $121 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.